PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial
August 08, 2024 08:00 ET
|
PMV Pharmaceuticals, Inc.
Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 60% of sites...
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
May 30, 2024 07:00 ET
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
May 29, 2024 07:00 ET
|
PMV Pharmaceuticals, Inc.
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation...
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
May 09, 2024 08:00 ET
|
PMV Pharmaceuticals, Inc.
First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors ...
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
March 27, 2024 08:00 ET
|
PMV Pharmaceuticals, Inc.
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2...
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
March 18, 2024 16:01 ET
|
PMV Pharmaceuticals, Inc.
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation...
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
February 29, 2024 16:01 ET
|
PMV Pharmaceuticals, Inc.
Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors...
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
February 26, 2024 08:00 ET
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
January 18, 2024 16:01 ET
|
PMV Pharmaceuticals, Inc.
Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash equivalents, and marketable securities totaling...
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
January 05, 2024 16:01 ET
|
PMV Pharmaceuticals, Inc.
PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs)Michael...